logo
Plus   Neg
Share
Email

Allergan: Atogepant Shows Robust Efficacy, Safety In Phase 2b/3 Trial

Allergan plc (AGN) announced positive results from CGP-MD-01, a Phase 2b/3 clinical trial evaluating the efficacy, safety, and tolerability of orally administered atogepant, a highly potent CGRP receptor antagonist in development for the prevention of migraine. The company said all active treatment arms of atogepant met the primary endpoint across all doses and dose regimens, with a statistically significant reduction from baseline in monthly migraine/probable migraine headache days in patients with episodic migraine treated with atogepant compared with placebo for 12 weeks.

In the CGP-MD-01 trial, atogepant was well tolerated. There was no signal of hepatotoxicity with atogepant in the study with daily administration over 12 weeks. The liver safety profile for atogepant was similar when compared to placebo.

Allergan said the company will continue with its phase 3 program for atogepant following discussions with regulatory authorities.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Chinese e-commerce giant Alibaba Group Holding Limited and rival JD.com have set new sales records for the "Singles Day" online shopping event. Alibaba said Sunday that it generated gross merchandise volume or GMV of 213.5 billion yuan, or $30.8 billion on November 11, 2018, representing an increase of 27 percent compared to 2017. The Singles Day shopping festival began in 2009. Japanese conglomerate SoftBank Group Corp. said Monday it has received approval from the Tokyo Stock Exchange for listing of common stock of its Japanese mobile telecoms unit, SoftBank Corp. SoftBank plans to sell shares worth 2.4 trillion yen, or $21 billion, in its domestic mobile telecom unit. This would make it the world's biggest IPO after Alibaba's $25 billion IPO in 2014. Shares of Infineon Technologies AG were losing around 4 percent in the morning trading in Germany after the semiconductor solutions company reported Monday weak net profit in its fourth quarter. Income from continuing operations, however, grew with strong revenue growth. The company also increased its full-year dividend.
Follow RTT